Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kling Biotherapeutics uses a proprietary platform to identify novel antibodies from patients to enable the generation of antibody and related biologic/cell therapies. Developer of antibody and antibody-derived drugs intended to treat cancer and infectious disease patients. The company's research utilizes a proprietary platform to identify novel antibodies from patients to enable the generation of antibodies and related biolog...
Kling Biotherapeutics uses a proprietary platform to identify novel antibodies from patients to enable the generation of antibody and related biologic/cell therapies. Developer of antibody and antibody-derived drugs intended to treat cancer and infectious disease patients. The company's research utilizes a proprietary platform to identify novel antibodies from patients to enable the generation of antibodies and related biological or cell therapies, helping medical personnel identify first-in-class druggable targets for human diseases.

List your booth number for exhibitions, ask us